Breaking Down Elanco Animal Health: 6 Analysts Share Their Views

Loading...
Loading...

In the latest quarter, 6 analysts provided ratings for Elanco Animal Health ELAN, showcasing a mix of bullish and bearish perspectives.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 2 2 1 0 1
Last 30D 0 1 0 0 0
1M Ago 0 0 0 0 0
2M Ago 1 0 0 0 1
3M Ago 1 1 1 0 0

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $16.25, with a high estimate of $20.00 and a low estimate of $12.50. This upward trend is evident, with the current average reflecting a 22.64% increase from the previous average price target of $13.25.

Diving into Analyst Ratings: An In-Depth Exploration

In examining recent analyst actions, we gain insights into how financial experts perceive Elanco Animal Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Balaji Prasad Barclays Raises Overweight $19.00 $18.00
Nathan Rich Goldman Sachs Raises Sell $12.50 $10.00
Jonathan Block Stifel Raises Buy $20.00 $13.00
Glen Santangelo Jefferies Announces Buy $17.00 -
Erin Wright Morgan Stanley Announces Overweight $16.00 -
Jonathan Block Stifel Raises Hold $13.00 $12.00

Key Insights:

  • Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Elanco Animal Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.
  • Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Elanco Animal Health compared to the broader market.
  • Price Targets: Understanding forecasts, analysts offer estimates for Elanco Animal Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

To gain a panoramic view of Elanco Animal Health's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Elanco Animal Health analyst ratings.

About Elanco Animal Health

Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Elanco Animal Health: Financial Performance Dissected

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Elanco Animal Health's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 4.09%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Elanco Animal Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -102.62%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): Elanco Animal Health's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -16.17%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.27%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: Elanco Animal Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.96.

Analyst Ratings: What Are They?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...